TREATMENT OF ACUTE RENAL ALLOGRAFT REJECTION WITH MONOCLONAL ANTI-T12 ANTIBODY1,2

作者：Robert L. Kirkman, José Lomelino Araújo, GEORGE J. BUSCH, Charles B. Carpenter, Edgar Louis Milford, Ellis L. Reinherz, Stuart F. Schlossman, Terry B. Strom, Nicholas L. Tilney · 发表于：Transplantation · 年份：1983 · DOI：10.1097/00007890-198336060-00005 · 被引用次数：96 · 研究领域：Renal Transplantation Outcomes and Treatments、Renal Diseases and Glomerulopathies、Complement system in diseases

Nineteen patients with acute rejection of a renal allograft were treated with the monoclonal antibody anti-T12, directed against a determinant present on all post-thymic T cells. Seven patients had a good response, four had an equivocal response, and eight failed to respond. Histologic studies demonstrated that the good responders had primarily cellular rejection. The nonresponders included 4 patients with moderate-to-severe humoral rejection, one patient with an inadequate dose of antibody, one patient who withdrew before completing the study, and one patient with late end-stage rejection. All eleven patients with good or equivocal responses have functioning kidneys in a follow-up of 1-15 months (mean 7 months). Only one patient has had a subsequent acute rejection episode, which responded to a steroid pulse. No significant complications of anti-T12 therapy occurred.